8-K: Silexion Therapeutics Highlights 2025 Wins, Eyes 2026 Clinical Trials

Silexion Therapeutics released a CEO letter detailing significant 2025 achievements, including positive preclinical data for SIL204, and outlining plans for Phase 2/3 clinical trial initiation in H1 2026.

Summary

• SIL204 demonstrated significant tumor inhibition, consistently exceeding 90%, in positive preclinical studies with activity across pancreatic, colorectal, and lung cancer models.
• Validated activity against eight distinct KRAS mutations, including G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D.
• Demonstrated preclinical efficacy across five different cancer types: pancreatic, colorectal, lung, gastric, and additional solid tumor models.
• Completed two-species toxicology studies confirming no systemic organ toxicity.
• Received positive written Scientific Advice from Germanys Federal Institute for Drugs and Medical Devices (BfArM) on Phase 2/3 trial design.
• Established strategic collaborations with Catalent for clinical manufacturing and AMS Advanced Medical Services as a contract research organization.
• Raised over $18 million in aggregate financing during 2025 and regained full Nasdaq compliance.
• Planned initiation of a Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer (LAPC) for the first half of 2026.
• Anticipate receiving a regulatory response from Israel during the first quarter of 2026 for trial commencement.
• Additional regulatory submissions are planned for Germany in Q1 2026, the European Union later in 2026, and a U.S. IND submission anticipated in H2 2026.
• The clinical trial will employ an innovative dual-route strategy combining intratumoral delivery for primary tumors with systemic administration for metastases.
• The initial safety run-in will evaluate this approach in combination with standard chemotherapy in approximately 18 patients, followed by a randomized study of approximately 166 patients.
• The company's platform seeks to address an estimated $30+ billion global KRAS-driven cancer market with its pan-KRAS therapeutic platform.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, detailing significant preclinical achievements, successful regulatory and operational milestones, and a clear path to human clinical trials for a promising therapy in a large unmet medical need. The tone is confident and forward-looking, backed by concrete progress.

Positives

• SIL204 showed significant tumor inhibition (>90%) in preclinical studies across multiple cancer models and KRAS mutations, indicating strong therapeutic potential.
• Successful completion of two-species toxicology studies with no systemic organ toxicity, a critical de-risking step for human clinical trials.
• Received positive regulatory feedback from Germanys BfArM on the Phase 2/3 trial design, suggesting alignment with regulatory expectations.
• Secured strategic collaborations with Catalent for clinical manufacturing and AMS Advanced Medical Services as a contract research organization, strengthening operational capabilities.
• Raised over $18 million in aggregate financing during 2025, providing capital for upcoming milestones.
• Regained full Nasdaq compliance, resolving a potential listing issue.
• Positioned lead asset, SIL204, to enter human clinical trials in H1 2026, marking a significant advancement.
• Targets a large and underserved KRAS-driven cancer market, estimated to exceed $30 billion annually, with a novel RNAi-based approach.

Risks

• Ability to successfully complete preclinical studies, proceed with planned regulatory submissions, and initiate clinical trials.
• Company's strategy, future operations, financial position, projected costs, prospects, and plans.
• Impact of the regulatory environment and compliance complexities.
• Expectations regarding future partnerships or other relationships with third parties.
• Future capital requirements and sources and uses of cash, including ability to obtain additional capital.
• Ability to maintain Nasdaq listing.
• Other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025.

Future Outlook

Silexion Therapeutics plans to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer in the first half of 2026, following anticipated regulatory approval from Israel in Q1 2026. Further regulatory submissions are planned for Germany in Q1 2026, the European Union later in 2026, and a U.S. IND submission in the second half of 2026. The company expects human data from the initial safety run-in (approx. 18 patients) in 2026 to be critical for demonstrating potential and attracting future collaborations and financing, aiming for SIL204 to become a first-in-class and first-line therapy for pancreatic cancer.

Management Comments

• "2025 was a transformational year for Silexion Therapeutics. We positioned our lead asset, SIL204, to enter human clinical trials in the first half of 2026, bringing us significantly closer to delivering breakthrough treatments for some of the most aggressive and difficult-to-treat cancers."
• "I believe Silexion is nearing an important inflection point."
• "I see SIL204 as a reflection of this next generation of cancer therapy, targeting KRAS at the genetic level and preventing the production of the mutated proteins that drive cancer growth from the outset."
• "We believe the long-term broader addressable market for our solution may exceed $30 billion annually when considering pancreatic, colorectal, and lung cancer treatment globally."
• "More importantly, over 80% of pancreatic cancer mortality is attributed to metastatic disease, a challenge that existing therapies have not adequately addressed. Our approach is designed specifically to target this unmet need."
• "We believe that the human data generated during the first stage of our clinical program in 2026 will be critical in demonstrating the potential of our approach and may serve as a foundation for future strategic collaborations and financing as we work to advance SIL204 toward a first-in-class and first-line therapy for pancreatic cancer."

Industry Context

The oncology landscape is rapidly evolving, with KRAS mutations remaining a challenging target despite strides in targeted cancer therapy. Existing KRAS inhibitors are mutation-specific, addressing a limited subset of alterations, and face limitations like restricted mutation coverage, drug resistance, and limited efficacy. Silexion's RNAi-based approach with SIL204 aims to overcome these limitations by silencing oncogenes at the genetic level, preventing mutated protein production, and targeting a broader range of KRAS mutations and cancer types, positioning it as a potential 'next generation' therapy in the estimated $10 billion (by 2032) KRAS inhibitor market, with Silexion's broader addressable market potentially exceeding $30 billion annually.

Comparison to Industry Standards

• Existing KRAS-targeted therapies are mutation-specific, addressing a limited subset of KRAS alterations, whereas SIL204 has validated activity against eight distinct KRAS mutations, indicating broader applicability.
• Current small molecule KRAS inhibitors face limitations such as restricted mutation coverage, drug resistance, and limited efficacy in certain tumor types; Silexion's RNAi approach aims to overcome these by targeting KRAS at the genetic level.
• Over 80% of pancreatic cancer mortality is attributed to metastatic disease, a challenge existing therapies have not adequately addressed; Silexion's innovative dual-route strategy (intratumoral and systemic) is specifically designed to target this unmet need.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress, de-risking of lead asset, clear path to clinical trials, and potential for future value creation and strategic collaborations. Regained Nasdaq compliance.
• Patients (KRAS-driven cancers): Potential for a breakthrough, first-in-class, and first-line therapy for aggressive and difficult-to-treat cancers, especially pancreatic cancer, addressing a significant unmet medical need.
• Employees: Positive outlook due to company progress and strategic direction.
• Partners (Catalent, AMS): Continued collaboration and potential for further engagement as trials progress.

Next Steps

• Anticipate regulatory response from Israel for Phase 2/3 clinical trial initiation during Q1 2026.
• Commence Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (LAPC) in H1 2026.
• Plan additional regulatory submissions to Germany in Q1 2026.
• Expect additional European Union submissions later in 2026.
• Anticipate U.S. IND submission in H2 2026.
• Conduct initial safety run-in in approximately 18 patients, assessing safety, tolerability, and preliminary efficacy.
• Following successful completion of the safety run-in, expand into a second stage randomized study of approximately 166 patients.
• Generate human data during the first stage of the clinical program in 2026 to potentially serve as a foundation for future strategic collaborations and financing.

Key Dates

Recommendation

Silexion Therapeutics has demonstrated substantial progress with its lead asset, SIL204, including compelling preclinical data showing significant tumor inhibition across multiple KRAS mutations and and cancer types. The successful completion of toxicology studies, positive regulatory feedback from BfArM, and established manufacturing and CRO partnerships significantly de-risk the upcoming Phase 2/3 clinical trial. The company has also strengthened its financial position by raising over $18 million and regained Nasdaq compliance. With a clear roadmap for clinical trial initiation in H1 2026 targeting a large, underserved KRAS-driven cancer market (estimated $30+ billion), the company is at a critical inflection point. The potential for a first-in-class RNAi therapy addressing the limitations of current mutation-specific KRAS inhibitors presents a compelling investment opportunity for long-term growth, despite the inherent risks of clinical development.

Keywords

Silexion Therapeutics, SIL204, KRAS-driven cancer, RNA interference, RNAi therapy, pancreatic cancer, colorectal cancer, lung cancer, oncology, clinical trials, biotechnology, preclinical data, Nasdaq, drug development, cancer treatment